Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthening the R&D network and diversifying product layout to help the company achieve “gradual, high-quality” growth. (Mainichi Keizai Shimbun)
信达证券4月24日发布研报称，给予万孚生物（300482.SZ）买入评级。评级理由主要包括：1）常规业务保持增长，盈利能力持续增强；2）加强研发布局，多元化的产品布局助力公司实现“有梯次、高质量”的增长。（每日经济新闻）
Cinda Securities released a research report on April 24 stating that it gave Wanfu Biotech (300482.SZ) a purchase rating. The main reasons for the rating include: 1) regular business continues to grow, and profitability continues to increase; 2) strengthe
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.